In February 2022, these guidelines were reviewed by an expert work group convened by
ASH. Review included limited searches for new evidence and discussion of the search …

Autoimmune heparin‐induced thrombocytopenia (aHIT) indicates the presence in patients of
anti‐platelet factor 4 (PF4)–polyanion antibodies that are able to activate platelets strongly …

Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy
caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic …

Blood contact with biomaterials triggers activation of multiple reactive mechanisms that can
impair the performance of implantable medical devices and potentially cause serious …

Background Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse
drug reaction that can lead to devastating thromboembolic complications, including …

The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …

Background: Heparin‐induced thrombocytopenia (HIT) is a prothrombotic adverse drug
reaction caused by heparin. As thrombocytopenia is common in hospitalized patients …

Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal,
immunologically mediated adverse drug reaction to unfractionated heparin or, less …

This chapter about the recognition, treatment, and prevention of heparin-induced
thrombocytopenia (HIT) is part of the Antithrombotic and Thrombolytic Therapy: American …

This chapter about the recognition, treatment, and prevention of heparin-induced
thrombocytopenia (HIT) is part of the Seventh ACCP Conference on Antithrombotic and …